Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Annals of HematologyOpen Access

Lenalidomide–rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXiaoli ChangHWHuanyuan WangYGYixian Guo

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows R2-MTX achieves 91.7% overall response in newly diagnosed PCNSL, indicating a viable alternative to ASCT.

Key Points

  • R2-MTX regimen resulted in a high overall response rate of 91.7% in patients with primary CNS lymphoma.
  • The combined treatment recorded a complete response rate of 66.7%, demonstrating its effectiveness at induction therapy's end.
  • Patients experienced a median progression-free survival of 62 months, supporting the regimen's long-term efficacy.
  • Management of treatment-related toxicities was relatively effective, with no severe adverse events reported.

Cite This Study

Chang et al. (2025) studied this question.

synapsesocial.com/papers/68e034f7f0e39f13e7fa32aahttps://doi.org/10.1007/s00277-025-06593-7
View Full Paper
Ask AI
Bookmark
Share